Abstract
A growing number of studies are reporting important roles played by long non-coding RNAs (lncRNAs) in various pathological and physiological processes. LncRNAs are implicated in numerous genomic regulatory functions at different levels, including regulation of transcription, post-transcriptional processes, genomic stability, and epigenetic genome modifications. Double homeobox A pseudogene 8 (DUXAP8), a novel lncRNA, has been reported to be involved in many cancers, including gastric, colorectal, esophageal, bladder, oral, ovarian, lung, and pancreatic cancers as well as hepatocellular carcinoma (HCC). DUXAP8 plays specific oncogenic roles via numerous malignancies promoting pathways. DUXAP8 is frequently dysregulated in multiple cancers, acting as a sponge to downregulate various tumor-suppressing microRNA activities. In this review, we comprehensively explore DUXAP8 expression and prognosis across cancer types, and systematically summarize current evidence concerning the functions and molecular mechanisms of DUXAP8 in tumorigenesis and progression. We conclude that DUXAP8 is a potential biomarker and therapeutic target for multiple cancers.
Highlights
Cancers collectively represent a life-threatening disease with major impact on public health
Ovarian Cancer Double homeobox A pseudogene 8 is markedly upregulated in ovarian cancer, where elevated expression is associated with shorter overall survival time (Lian et al, 2018; Li J.R. et al, 2021)
Expression of the novel long noncoding RNAs (lncRNAs) Double homeobox A pseudogene 8 (DUXAP8) has been described in various cancers
Summary
Cancers collectively represent a life-threatening disease with major impact on public health (the second leading cause of death worldwide). Researchers have detected substantially elevated lncRNA DUXAP8 expression in bladder cancer tissues compared with adjacent normal tissues (Lin et al, 2018). Patients with higher DUXAP8 expression were associated with shorter overall survival times (Wei et al, 2020).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
